[Intensive care treatment for neuroleptic malignant syndrome]

Anasthesiol Intensivmed Notfallmed Schmerzther. 2010 Jul;45(7-8):448-55. doi: 10.1055/s-0030-1262471. Epub 2010 Jul 21.
[Article in German]

Abstract

We report a case of severe neuroleptic malignant syndrome developing in a 28-year-old female patient following deliberate self-poisoning with atypical antipsychotic drugs and serotonin reuptake inhibitors. Because of an increasing loss of consciousness she was rapidly transferred to an Intensive Care Unit. Following this, she became progressively febrile associated with rhabdomyolysis and life-threatening organ dysfunctions. Due to fast diagnosis and immediate therapy the patient was treated successfully. This article describes etiology, pathophysiology and symptoms of neuroleptic malignant syndrome. In addition therapeutic options are discussed.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antidepressive Agents / adverse effects
  • Antidepressive Agents / therapeutic use
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use
  • Benzodiazepines / adverse effects
  • Benzodiazepines / therapeutic use
  • Bipolar Disorder / complications
  • Bipolar Disorder / drug therapy
  • Coma / chemically induced
  • Creatine Kinase / blood
  • Critical Care*
  • Dantrolene / therapeutic use
  • Female
  • Humans
  • Muscle Relaxants, Central / therapeutic use
  • Myoglobin / blood
  • Neuroleptic Malignant Syndrome / diagnosis
  • Neuroleptic Malignant Syndrome / drug therapy
  • Neuroleptic Malignant Syndrome / therapy*
  • Olanzapine
  • Sertraline / adverse effects
  • Sertraline / therapeutic use
  • Treatment Outcome

Substances

  • Antidepressive Agents
  • Antipsychotic Agents
  • Muscle Relaxants, Central
  • Myoglobin
  • Benzodiazepines
  • Creatine Kinase
  • Dantrolene
  • Olanzapine
  • Sertraline